TY - JOUR
T1 - Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy
T2 - Insights from saturn
AU - Puri, Rishi
AU - Nissen, Steven E.
AU - Shao, Mingyuan
AU - Ballantyne, Christie M.
AU - Barter, Phillip J.
AU - Chapman, M. John
AU - Erbel, Raimund
AU - Libby, Peter
AU - Raichlen, Joel S.
AU - Uno, Kiyoko
AU - Kataoka, Yu
AU - Nicholls, Stephen J.
N1 - Publisher Copyright:
© 2014 American College of Cardiology Foundation.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - RESULTS Compared with men (n =765), women (n =274) were older (p < 0.001) and more likely to have hypertension (p < 0.001), diabetes (p =0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p =0.01), high-density lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p =0.004) levels. At follow-up, women had higher high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p =0.46) levels compared with men. Compared with men, women had lower baseline PAV (34.0 ± 8.0% vs. 37.2 ± 8.2%, p < 0.001) and TAV (122.4 ± 55 mm3 vs. 151.9 ± 63 mm3, p < 0.001), yet demonstrated greater PAV regression (-1.52 ± 0.18% vs. -1.07 ± 0.10%, p =0.03) and TAV regression (-8.27 ± 0.9 mm3 vs. -6.59 ± 0.50 mm3, p =0.11) following treatment. Greater PAV regression in women versus men occurred with rosuvastatin (p =0.004), those with diabetes (p =0.01), stable coronary disease (p =0.01), higher baseline LDL-C (p =0.02), and higher CRP (p =0.04) levels. On multivariable analysis, female sex was independently associated with PAV regression (p =0.01), and a sex-treatment interaction was found (p =0.036). For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (-1.81 ± 0.22% vs. -1.12 ± 0.13%, p =0.007) and TAV regression (-10.1 ± 1.1 mm3 vs. -7.16 ± 0.65 mm3, p =0.023) than men, whereas PAV and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy. This benefit appears in the setting of lower on-treatment LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img 2014;7:1013-22.OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy.BACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease.METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in change from baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or clinical outcomes.
AB - RESULTS Compared with men (n =765), women (n =274) were older (p < 0.001) and more likely to have hypertension (p < 0.001), diabetes (p =0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p =0.01), high-density lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p =0.004) levels. At follow-up, women had higher high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p =0.46) levels compared with men. Compared with men, women had lower baseline PAV (34.0 ± 8.0% vs. 37.2 ± 8.2%, p < 0.001) and TAV (122.4 ± 55 mm3 vs. 151.9 ± 63 mm3, p < 0.001), yet demonstrated greater PAV regression (-1.52 ± 0.18% vs. -1.07 ± 0.10%, p =0.03) and TAV regression (-8.27 ± 0.9 mm3 vs. -6.59 ± 0.50 mm3, p =0.11) following treatment. Greater PAV regression in women versus men occurred with rosuvastatin (p =0.004), those with diabetes (p =0.01), stable coronary disease (p =0.01), higher baseline LDL-C (p =0.02), and higher CRP (p =0.04) levels. On multivariable analysis, female sex was independently associated with PAV regression (p =0.01), and a sex-treatment interaction was found (p =0.036). For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (-1.81 ± 0.22% vs. -1.12 ± 0.13%, p =0.007) and TAV regression (-10.1 ± 1.1 mm3 vs. -7.16 ± 0.65 mm3, p =0.023) than men, whereas PAV and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy. This benefit appears in the setting of lower on-treatment LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img 2014;7:1013-22.OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy.BACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease.METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in change from baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or clinical outcomes.
KW - IVUS
KW - atherosclerosis
KW - atorvastatin
KW - rosuvastatin
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=84908038000&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2014.04.019
DO - 10.1016/j.jcmg.2014.04.019
M3 - Article
C2 - 25240453
AN - SCOPUS:84908038000
SN - 1936-878X
VL - 7
SP - 1013
EP - 1022
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 10
ER -